Aqix Ltd is a healthcare company that has identified valuable niche opportunities in clinical development for it's lead technology AQIX® RS-I, in the specific areas of infusion therapy, organ transplant perfusion and cell or tissue biospecimen collection and preservation.
In the management of hypovolaemia, AQIX® RS-I, is the first in a new generation of therapeutic products that focuses on maintaining homeostasis using the essential factors and mechanisms found in human serum and interstitial fluid-gels, at their normal physiological concentrations.
It is an exquisite and simple concept that is very easy to market to clinicians. The company has patents covering the formulation, manufacturing process and use of its innovation.
Aqix Ltd is committed to improving patients’ quality of life wherever needed: whether in hospitals, medical centres or at the point of diagnosis through personalised medicine.